Featured Research

from universities, journals, and other organizations

Gynecologist disputes findings from global study of ovarian cancer

Date:
October 15, 2010
Source:
St. Joseph's Hospital and Medical Center
Summary:
A gynecologic oncologist is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.

An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.

Related Articles


Published in The Lancet last month, the study reported that women who received early chemotherapy for a recurrence of ovarian cancer did not live longer than those whose treatment is delayed.

"While this study is a bold challenge to the assumption of early treatment, there are several significant problems with the findings," says Bradley Monk, MD, and a leader in developing new approaches to cancer treatments. "Our focus should no longer be on standard chemotherapy, but on targeted genetics-based treatments."

Dr. Monk expressed his concerns about the ovarian cancer study in an editorial in The Lancet. He and Dr. Robert Morris, of Wayne State University, wrote that finding the relevant therapy is far more important than timing when treating ovarian cancer. "The most troubling problem with the trial is that contemporary therapies were not available to most of the participants," says Dr. Monk. "This lack of availability is related not only to the chronological length of the trial (which started in 1996), but also to regulatory and financial barriers restricting access to all active compounds in the participating countries."

In the study, survival rates were not significantly different between those who started chemotherapy once a higher concentration of cancer-related proteins were detected and those whose treatment was delayed until they had clinical symptoms.

A total of 1,442 women from 59 centers around the world registered for the trial, and 529 were randomly assigned to treatment groups. About 70 percent of the women died. Of the 370 deaths, 186 occurred in the early treatment group and 184 in the delayed treatment. Median survival was 25.7 months for those on early treatment and 27.1 months for those on delayed treatment.


Story Source:

The above story is based on materials provided by St. Joseph's Hospital and Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Robert T Morris, Bradley J Monk. Ovarian cancer: relevant therapy, not timing, is paramount. The Lancet, 2010; 376 (9747): 1120 DOI: 10.1016/S0140-6736(10)61515-2

Cite This Page:

St. Joseph's Hospital and Medical Center. "Gynecologist disputes findings from global study of ovarian cancer." ScienceDaily. ScienceDaily, 15 October 2010. <www.sciencedaily.com/releases/2010/10/101015150933.htm>.
St. Joseph's Hospital and Medical Center. (2010, October 15). Gynecologist disputes findings from global study of ovarian cancer. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/2010/10/101015150933.htm
St. Joseph's Hospital and Medical Center. "Gynecologist disputes findings from global study of ovarian cancer." ScienceDaily. www.sciencedaily.com/releases/2010/10/101015150933.htm (accessed March 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins